Galmed Pharmaceuticals Ltd. (GLMD) Dividend History

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for liver diseases. The company's lead product candidate, Aramchol, is a bile acid derivative developed for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Galmed also explores other therapeutic options targeting liver and metabolic conditions.

Website: https://www.galmedpharma.com

Dividend History

Galmed Pharmaceuticals Ltd. currently does not pay dividends

Company News

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Galmed Pharmaceuticals has launched a collaboration with Virginia Commonwealth University to investigate its drug Aramchol's potential in overcoming drug resistance in gastrointestinal cancers, including colorectal and liver cancers.

Benzinga
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

The Motley Fool

Featured Companies: ETNB GALT IQV MDGL SGMT TERN VKTX
Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade

Galmed Pharmaceuticals (GLMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research

Page data last updated 07/22/2025 22:05:31 UTC